Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12525071 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20495533 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL33171 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30957093 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29666504 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23855805 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13749875 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5620296 | 0.92 | PSEN1 (0.85) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4419147 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3046688 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023077133-A2 | CONTROLLING HOMEOSTATIC REGULATORY CIRCUITRY IN HYPOTHALAMUS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-04 | — | — | WO | claimed |
| EP-3986569-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG (CH) | 2022-04-27 | — | — | EP | claimed |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | NOVARTIS AG (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| EP-3970725-B1 | A GAMMA SECRETASE INHIBITOR FOR TREATING HEARING LOSS | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4569086-A1 | 3D ISLET FORMATION FROM ENDOCRINE PROGENITOR CELLS | Spiber Technologies AB (SE) | 2025-06-18 | — | — | EP | disclosed |
| EP-4569085-A1 | IN VITRO DERIVATION OF PANCREATIC ISLETS FROM HUMAN PLURIPOTENT STEM CELLS | Spiber Technologies AB (SE) | 2025-06-18 | — | — | EP | disclosed |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | NOVARTIS AG (CH) | 2025-04-15 | — | — | US | disclosed |
| CN-119679936-A | Dosing regimen and combination therapy for multispecific antibodies directed against B cell maturation antigens | 诺华股份有限公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| EP-3986569-A1 | DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN | Novartis AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3975926-A1 | A BIOCOMPATIBLE MEMBRANE COMPOSITE | W.L. Gore & Associates, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3975925-A1 | A BIOCOMPATIBLE MEMBRANE COMPOSITE | W.L. Gore & Associates, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3976236-A1 | A BIOCOMPATIBLE MEMBRANE COMPOSITE | W.L. Gore & Associates Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114286828-A | Dosing regimens and combination therapies for multispecific antibodies targeting B cell maturation antigens | 诺华股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3972634-A2 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-03-24 | — | — | US | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035473-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOFPrivate view | BCL9, BRCA1, VCAM1 | PSEN1 529/4885PSEN2 884/4885APH1B 1103/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | PSEN1 13/4885PSEN2 47/4885APH1B 39/4885 |
| US-12624118-B2 | Trispecific binding molecules against BCMA and uses thereof | CD2, CD40, CD22 | PSEN1 1744/4885PSEN2 2511/4885APH1B 2583/4885 |
| US-12275795-B2 | Binding molecules against BCMA and uses thereof | EPCAM, CD40, BCR | PSEN1 4521/4885PSEN2 4758/4885APH1B 4252/4885 |
| US-20220088010-A1 | Co-Administration of inhibitors to produce insulin producing gut cells | IAPP, GPR119, FOXO1 | PSEN1 878/4885PSEN2 1493/4885APH1B 529/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | PSEN1 170/4885PSEN2 319/4885APH1B 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.